WT1 and melanoma: We have recently introduced a model of “circular economy” by repurposing the non-transplantable UCB units, to obtain dendritic cell (DC) doses at a ×109 scale and subsequently facilitate the yield of clinically relevant quantities of third-party, bivalent leukemia-specific T-cells (Leuk-STs), targeting Wilms tumor 1 (WT1) and preferentially expressed antigen in melanoma (PRAME) [35].